1. Ågren H, Lundqvist G. Low levels of somatostatin in human CSF mark depressive episodes. Psychoneuroendocrinology 1984;9:233–248.

2. Altemus M, Pigott T, L'Heureux F, et al. CSF somatostatin in obsessive-compulsive disorder. Am J Psychiatry 1993;150:460–464.

3. Amsterdam JD, Maislin G, Winokur A, Berwish N, Kling M, Gold P. The oCRH test before and after clinical recovery from depression. J Affect Dis 1988;14:213–222.

4. Amsterdam JD, Marinelli DL, Arger P, Winokur A. Assessment of adrenal gland volume by computed tomography in depressed patients and healthy volunteers: a pilot study. Psychiatry Res 1987; 21:189–197.

5. Arato M, Banki CM, Bissette G, Nemeroff CB. Elevated CSF CRF in suicide victims. Biol Psychiatry 1989;25:355–359.

6. Arnold MA, Reppert SM, Rorstad OP, et al. Temporal patterns of somatostatin immunoreactivity in the cerebrospinal fluid of the rhesus monkey: effect of environmental lighting. J Neurosci 1982; 2:674–680.

7. Banki CM, Bissette G, Arato M, Nemeroff CB. Elevation of immunoreactive CSF TRH in depressed patients. Am J Psychiatry 1988; 145:1526–1531.

8. Banki CM, Karmacsi L, Bissette G, Nemeroff CB. Cerebrospinal fluid neuropeptides in mood disorder and dementia. J Affect Dis 1992;25:39–45.

9. Banki CM, Karmacsi L, Bissette G, Nemeroff CB. CSF corticotropin-releasing hormone and somatostatin in major depression: response to antidepressant treatment and relapse. Eur Neuropsychopharmacol 1992;2:107–113.

10. Bartalena L, Placidi GF, Martino E, et al. Nocturnal serum thyrotropin (TSH) surge and the TSH response to TSH-releasing hormone: dissociated behavior in untreated depressives. J Clin Endocrinol Metab 1990;71(3):650–655.

11. Berrettini WH, Nurnberger JL Jr, Zerbe RL, Gold PW, Chrousos GP, Tomai T. CSF neuropeptides in euthymic bipolar patients and controls. Br J Psychiatry 1987;150:208–212.

12. Bissette G, Widerlöv E, Walléus H, et al. Alterations in cerebrospinal fluid concentrations of somatostatinlike immunoreactivity in neuropsychiatric disorders. Arch Gen Psychiatry 1986;43:1148–1151.

13. Black PMcL, Ballantine HT Jr, Carr DB, Beal MF, Martin JB. Beta-endorphin and somatostatin concentrations in the ventricular cerebrospinal fluid of patients with affective disorder. Biol Psychiatry 1986;21:1075–1077.

14. Bowen DM, Najlerahim A, Procter AW, Francis PT, Murphy E. Circumscribed changes of the cerebral cortex in neuropsychiatric disorders of later life. Proc Natl Acad Sci USA 1989;86:9504–9508.

15. Charlton BG, Leake A, Wright C, et al. Somatostatin content and receptors in the cerebral cortex of depressed and control subjects. J Neurol Neurosurg Neuropsychiatry 1988;51:719–721.

16. Dallman MF. Regulation of adrenocortical function following stress. In: Brown MR, Koob GF, Rivier C, eds. Stress neurobiology and neuroendocrinology. New York: Marcel Dekker; 1991:173–192.

17. Davis KL, Davidson M, Yang R-K, et al. CSF somatostatin in Alzheimer's disease, depressed patients, and control subjects. Biol Psychiatry 1988;24:710–712.

18. DeBellis MD, Gold PW, Geracioti TD, Listwak S, Kling MA. Fluoxetine significantly reduces CSF CRH and AVP concentrations in patients with major depression. Am J Psychiatry 1993;150:656–657.

19. Doran AR, Rubinow DR, Roy A, Pickar D. CSF somatostatin and abnormal response to dexamethasone administration in schizophrenic and depressed patients. Arch Gen Psychiatry 1986;43:365–369.

20. Dunn AJ, Berridge CW. Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses? Brain Res Rev 1990;15:71–100.

21. Duval F, Macher JP, Mokrani MC. Difference between evening and morning thyrotropin response to protirelin in major depressive episode. Arch Gen Psychiatry 1990;47:443–448.

22. Eccles J. Chemical transmission and Dale's principle. In: Hökfelt T, Fuxe K, Pernow B, eds. Progress in Brain Research. Amsterdam: Elsevier; 1986:3–13.

23. Fossey MD, Lydiarel RB, Larara MT, Bissette G, Nemeroff CB, Balleyer JC. CSF thyrotropin-releasing hormone in patients with anxiety disorders. Biol Psychiatry 1990;27(Suppl):167A.

24. Garrick NA, Hill JL, Szele FG, Tomai TP, Gold PW, Murphy DL. Corticotropin-releasing factor: a marked circadian rhythm in primate cerebrospinal fluid peaks in the evening and is inversely related to the cortisol circadian rhythm. Endocrinology 1987; 121:1329–1334.

25. Gerner RH, Yamada T. Altered neuropeptide concentrations in cerebrospinal fluid of psychiatric patients. Brain Res 1982;238:298–302.

26. Gertz BJ, Cantreras LN, McComb DJ, Kovacs K, Tyrrell JB, Dallman MF. Chronic administration of corticotropin-releasing factor increases pituitary corticotroph number. Endocrinology 1987; 120:381–388.

27. Gold MS, Pottash AL, Extein I. Hypothyroidism and depression. Evidence from complete thyroid function evaluation. JAMA 1981;245(19):919–922.

28. Gold PW, Loriaux DL, Roy A, et al. Responses to corticotropin-releasing hormone in the hypercortisolism of depression and Cushing's disease. Pathophysiologic and diagnostic implications. New Engl J Med 1986;314:1329–1335.

29. Haggerty JJ Jr, Garbutt JC, Evans DL, Simon JS, Nemeroff CB. Subclinical hypothyroidism: a review of neuropsychiatric aspects. Int J Psychiatry Med 1990;20:193–208.

30. Hauger RL, Lorang M, Irwin M, Aguilera G. CRF receptor regulation and sensitization of ACTH responses to acute ether stress during chronic intermittent immobilization stress. Brain Res 1990; 532:34–40.

31. Henn FA, McKinney WT. Animal models in psychiatry. In: Meltzer HY, ed. Psychopharmacology: the third generation. New York: Raven Press; 1987:687–696.

32. Hökfelt T. Neuropeptides in perspective: the last ten years. Neuron 1991;7:867–879.

33. Holsboer F, Gerken A, Stalla GK, Muller OA. Blunted aldosterone and ACTH release after human corticotropin-releasing factor administration in depressed patients. Am J Psychiatry 1987;144:229–231.

34. Howland RH. Thyroid dysfunction in refractory depression: implications for pathophysiology and treatment. J Clin Psychiatry 1993;54:47–54.

35. Joffee RT, Sokolov TH. Thyroid hormones, the brain, and affective disorders. Crit Rev Neurobiol 1994;8:45–63.

36. Jolkkonen J, Lepola U, Bissette G, Nemeroff CB, Riekkinen P. CSF corticotropin-releasing factor is not affected in panic disorder. Biol Psychiatry 1993;33:136–138.

37. Kakigi T, Maeda K, Kaneda H, Chihara K. Repeated administration of antidepressant drugs reduces regional somatostatin concentrations in rat brain. J Affect Dis 1992;25(4):215–220.

38. Kaye WH, Gwirtsman HE, George DT, et al. Elevated cerebrospinal fluid levels of immunoreactive corticotropin-releasing hormone in anorexia nervosa; relation to state of nutrition, adrenal function, and intensity of depression. J Clin Endocrinol Metab 1987;64:203–208.

39. Kaye WH, Rubinow D, Gwirtsman HE, George DT, Jimerson DC, Gold PW. CSF somatostatin in anorexia nervosa and bulimia: relationship to the hypothalamic pituitary-adrenal cortical axis. Psychoneuroendocrinology 1988;13:265–272.

40. Kirkegaard C. The thyrotropin response to thyrotropin-releasing hormone in endogenous depression. Psychoneuroendocrinology 1981;6:189–212.

41. Kling MA, Rubinow DR, Doran AR, et al. Cerebrospinal fluid immunoreactive somatostatin concentrations in patients with Cushing's disease and major depression: relationship to indicies of corticotropin-releasing hormone and cortisol secretion. Neuroendocrinology 1993;57:79–88.

42. Koob GF, Heinrichs SC, Pich EM, et al. The role of CRF in behavioral responses to stress. In: Chadwick DJ, Marsh J, Ackrill K, eds. CIBA Foundation Symposium #172. New York: John Wiley; 1993:277–295.

43. Krishnan KRR. Pituitary and adrenal changes in depression. Psychiatric Ann 1993;23:671–675.

44. Krishnan KRR, Rayasam K, Reed DR, et al. The corticotropin-releasing factor stimulation test in patients with major depression: relationship to dexamethasone suppression test results. Depression 1993;1:133–136.

45. Kruesi MJP, Swedo S, Leonard H, Rubinow DR, Rapoport JL. CSF somatostatin in childhood psychiatric disorders: a preliminary investigation. Psychiatry Res 1990;33:277–284.

46. Kubek MJ, Sattin A. Effect of electroconvulsive shock on the content of thyrotropin-releasing hormone in rat brain. Life Sci 1984; 34:1149–1152.

47. Langer G, Koinig G, Hatzinger R, et al. Response of thyrotropin to thyrotropin-releasing hormone as predictor of treatment outcome. Arch Gen Psychiatry 1986;43:861–868.

48. Loosen PT. Pituitary-thyroid axis in affective disorders. In: Meltzer HY, ed. Psychopharmacology: the third generation. New York: Raven Press; 1987:629–636.

49. Maeda K, Yoshimoto Y, Yamadori A. Blunted TSH and unaltered PRL responses to TRH following repeated administration of TRH in neurologic patients: a replication of neuroendocrine features of major depression. Biol Psychiatry 1993;33:277–283.

50. Meaney MJ, Mitchell JB, Aitken DH, et al. The effects of neonatal handling on the development of the adrenocortical response to stress: implications for neuropathology and cognitive deficits in later life. Psychoneuroendocrinology 1991;16:85–103.

51. Molchan SE, Lawlor BA, Hill JL, et al. CSF monoamine metabolites and somatostatin in Alzheimer's disease and major depression. Biol Psychiatry 1991;29:1110–1118.

52. Nemeroff CB. The relevace of thyrotropin-releasing hormone to psychiatric disorders. In: Nemeroff CB, ed. Progress in psychiatry, neuropeptides and psychiatric disease. Washington DC: American Psychiatric Association Press; 1990:15–28.

53. Nemeroff CB, Bissette G, Akil H, Fink M. Neuropeptide concentrations in the cerebrospinal fluid of depressed patients treated with electroconvulsive therapy: corticotropin-releasing factor, b-endorphin and somatostatin. Br J Psychiatry 1991;158:59–63.

54. Nemeroff CB, Bissette G, Martin JB, et al. Effect of chronic treatment with thyrotropin-releasing hormone (TRH) or an analog of TRH (linear b-alanine TRH) on the hypothalamic-pituitary-thyroid axis. Neuroendocrinology 1980;30:193–199.

55. Nemeroff CB, Krishnan KRR, Reed D, Leder R, Beam C, Dunnick NR. Adrenal gland enlargement in major depression: a computed tomography study. Arch Gen Psychiatry 1992;49:384–387.

56. Nemeroff CB, Owens MJ, Bissette G, Andorn AC, Stanley M. Reduced corticotropin-releasing factor (CRF) binding sites in the frontal cortex of suicides. Arch Gen Psychiatry 1988;45:577–579.

57. Nemeroff CB, Widerlov E, Bissette G, et al. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science 1984;226:1342–1344.

58. Owens MJ, Nemeroff CB. The physiology and pharmacology of corticotropin releasing factor. Pharmacol Rev 1992;43:425–473.

59. Pepin MC, Pothier F, Barden N. Antidepressant drug action in a transgenic mouse model of the endocrine changes seen in depression. Mol Pharmacol 1992;42(6):991–995.

60. Plotnikoff NP, Prange AJ Jr, Breese GR, Anderson MS, Wilson IC. Thyrotropin releasing hormone: enhancement of DOPA activity by a hypothalamic hormone. Science 1972;178:417–418.

61. Plotsky PM. Pathways to the secretion of ACTH: a view from the portal. J Neuroendocrinol 1991;3:1–9.

62. Plotsky P, Meaney M. Early postnatal experience alters hypothalamic corticotropin-releasing factor (CRF) mRNA, median eminence CRF content, and stress-induced release in adult rats. Mol Brain Res 1993;18:195–200.

63. Post RM. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am J Psychiatry 1992;149(8):999–1010.

64. Post PM. Models for the impact of affective illness on gene expression. Clin Neurosci 1993;1:129–138.

65. Post RM, Gold P, Rubinow DR, Ballenger JC, Bunney WE, Goodwin FK. Peptides in cerebrospinal fluid of neuropsychiatric patients: an approach to central nervous system peptide function. Life Sci 1982;31:1–15.

66. Post RM, Weiss SRB. Endogenous biochemical abnormalities in affective illness: therapeutic versus pathogenic. Biol Psychiatry 1992;32:469–484.

67. Risch SC, Lewine RJ, Jewart RD, et al. Relationship between cerebrospinal fluid peptides and neurotransmitters in depression. In: Risch SC, ed. Central nervous system peptide mechanisms in stress and depression. Washington DC: American Psychiatric Press; 1991:93–103.

68. Rothschild AJ. The dexamethasone suppression test in psychiatric disorders. Psychiatric Ann 1993;23:662–670.

69. Roy A, Bissette G, Nemeroff CB. Cerebrospinal fluid thyrotropin-releasing hormone concentrations in alcoholics and normal controls. Biol Psychiatry 1990;28:767–772.

70. Roy-Byrne PP, Uhde TW, Post RM, Gallucci W, Chrousos GP, Gold PW. The corticotropin-releasing hormone stimulation test in patients with panic disorder. Am J Psychiatry 1986;143:896–899.

71. Rubin RT, Phillips JJ. Adrenal gland enlargement in major depression [letter]. Arch Gen Psychiatry 1993;50:833–835.

72. Rubinow DR. Cerebrospinal fluid somatostatin and psychiatric illness. Biol Psychiatry 1986;21:341–365.

73. Rubinow DR, Gold PW, Post RM. CSF somatostatin in affective illness. Arch Gen Psychiatry 1983;40:409–412.

74. Rubinow DR, Post RM, Gold PW, Ballenger JC, Reichlin S. Effects of carbamazepine on cerebrospinal somatostatin. Psychopharmacology 1985;85:210–213.

75. Russ MJ, Ackerman SH. Antidepressant treatment response in depressed hypothyroid patients. Hosp Community Psychiatry 1989; 40:954–956.

76. Sapolsky RM, Plotsky PM. Hypercortisolism and its possible neural basis. Biol Psychiatry 1990;27:937–952.

77. Schlesser MA, Rush AJ, Fairchild C, Crowley G, Orsulak P. The thyrotropin-releasing hormone stimulation test: a methodological study. Psychiatry Res 1983;9:59–67.

78. Shelton RC, Winn S, Ekhatore N, Loosen PT. The effects of antidepressants on the thyroid axis in depression. Biol Psychiatry 1993;33:120–126.

79. Smith MA, Davidson J, Ritchie JC, et al. The corticotropin-releasing hormone test in patients with post-traumatic stress disorder. Biol Psychiatry 1989;26:349–355.

80. Sorensen KV. Rapid post-mortem decomposition of the somatostatin cells in human brain. An immunohistochemical examination. Biomed Pharmacother 1984;38:458–461.

81. Stenzel-Poore MP, Cameron VA, Vaughan J, Sawchenko PE, Vale W. Development of Cushing's syndrome in corticotropin-releasing factor transgenic mice. Endocrinology 1992;30(6):3378–3386.

82. Sunderland T, Rubinow DR, Tariot PN, et al. CSF somatostatin in patients with Alzheimer's disease, older depressed patients, and age-matched control subjects. Am J Psychiatry 1987;144:1313–1316.

83. Vale W, Spiess J, Rivier C, Rivier J. Characterization of a 41 residue ovine hypothalamic peptide that stimulates secretion of corticotropin of b-endorphin. Science 1981;213:1394–1397.

84. Whybrow PC, Prange AJ. A hypothesis of thyroid-catecholamine receptor interaction. Arch Gen Psychiatry 1981;38:106–113.

85. Young EA, Watson SJ, Kotun J, et al. b-lipotropin/b-endorphin response to low-dose ovine corticotropin releasing factor in endogenous depression. Arch Gen Psychiatry 1990;47:449–457.

86. Zis KD, Zis A. Increased adrenal weight in victims of violent suicide. Am J Psychiatry 1987;144:1214–1215.